Tallying Up the Dx Score Card
An overview of the diagnostics industry's year-to-date performance is not inspiring. Total industry sales are expected to be down 2-3% this year from last year, analysts say. The top eight diagnostics companies have an increasing percentage of the business. Hardest hit were immunoassay and clinical chemistry segments; best-performers were nucleic acid probes and diabetes care.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
BeiGene gets a new chief business executive and there are new CMOs at Cellectar Biopharma, MacroGenics and Reata Pharmaceuticals.
A new EU pilot will help drug regulators and policymakers understand the factors influencing the uneven availability of centrally authorized medicines in the member states.